Overexpression of NAT10 induced platinum drugs resistance in breast cancer cell.
10.3760/cma.j.cn112152-20211231-00986
- Author:
Pan QI
1
;
Ya Ke CHEN
2
;
Rui Li CUI
2
;
Rui Juan HENG
1
;
Sheng XU
1
;
Xiao Ying HE
1
;
Ai Min YUE
1
;
Jiang Kun KANG
2
;
Hao Han LI
2
;
Yong Xin ZHU
2
;
Cong WANG
2
;
Yu Lu CHEN
2
;
Kua HU
2
;
Yan Yan YIN
2
;
Li Xue XUAN
3
;
Yu SONG
2
Author Information
1. Department of Head and Neck Breast, Xinxiang Central Hospital, the Fourth Affiliated Hospital of Xinxiang Medical College, Xinxiang 453000, China.
2. College of Pharmacology, Xinxiang Medical University, Xinxiang 453000, China.
3. Department of Breast, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
N-acetyltransferase 10;
PARP1
- MeSH:
Breast Neoplasms/enzymology*;
Cell Line, Tumor;
Drug Resistance, Neoplasm;
Female;
Humans;
MCF-7 Cells;
N-Terminal Acetyltransferases/metabolism*;
Organoplatinum Compounds/pharmacology*;
Oxaliplatin/pharmacology*;
X-ray Repair Cross Complementing Protein 1
- From:
Chinese Journal of Oncology
2022;44(6):540-549
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the platinum drugs resistance effect of N-acetyltransferase 10 (NAT10) overexpression in breast cancer cell line and elucidate the underlining mechanisms. Methods: The experiment was divided into wild-type (MCF-7 wild-type cells without any treatment) group, NAT10 overexpression group (H-NAT10 plasmid transfected into MCF-7 cells) and NAT10 knockdown group (SH-NAT10 plasmid transfected into MCF-7 cells). The invasion was detected by Transwell array, the interaction between NAT10 and PARP1 was detected by co-immunoprecipitation. The impact of NAT10 overexpression or knockdown on the acetylation level of PARP1 and its half-life was also determined. Immunostaining and IP array were used to detect the recruitment of DNA damage repair protein by acetylated PARP1. Flow cytometry was used to detect the cell apoptosis. Results: Transwell invasion assay showed that the number of cell invasion was 483.00±46.90 in the NAT10 overexpression group, 469.00±40.50 in the NAT10 knockdown group, and 445.00±35.50 in the MCF-7 wild-type cells, and the differences were not statistically significant (P>0.05). In the presence of 10 μmol/L oxaliplatin, the number of cell invasion was 502.00±45.60 in the NAT10 overexpression group and 105.00±20.50 in the NAT10 knockdown group, both statistically significant (P<0.05) compared with 219.00±31.50 in wild-type cells. In the presence of 10 μmol/L oxaliplatin, NAT10 overexpression enhanced the binding of PARP1 to NAT10 compared with wild-type cells, whereas the use of the NAT10 inhibitor Remodelin inhibited the mutual binding of the two. Overexpression of NAT10 induced PARP1 acetylation followed by increased PARP1 binding to XRCC1, and knockdown of NAT10 expression reduced PARP1 binding to XRCC1. Overexpression of NAT10 enhanced PARP1 binding to LIG3, while knockdown of NAT10 expression decreased PARP1 binding to LIG3. In 10 μmol/L oxaliplatin-treated cells, the γH2AX expression level was 0.38±0.02 in NAT10 overexpressing cells and 1.36±0.15 in NAT10 knockdown cells, both statistically significant (P<0.05) compared with 1.00±0.00 in wild-type cells. In 10 μmol/L oxaliplatin treated cells, the apoptosis rate was (6.54±0.68)% in the NAT10 overexpression group and (12.98±2.54)% in the NAT10 knockdown group, both of which were statistically significant (P<0.05) compared with (9.67±0.37)% in wild-type cells. Conclusion: NAT10 overexpression enhances the binding of NAT10 to PARP1 and promotes the acetylation of PARP1, which in turn prolongs the half-life of PARP1, thus enhancing PARP1 recruitment of DNA damage repair related proteins to the damage sites, promoting DNA damage repair and ultimately the survival of breast cancer cells.
